These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 19190817

  • 1. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C, Omran H, Tripp C, Poetzsch B.
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [Abstract] [Full Text] [Related]

  • 2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.
    G Ital Nefrol; 2010 Feb; 27(6):649-54. PubMed ID: 21132647
    [Abstract] [Full Text] [Related]

  • 3. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D.
    Circulation; 2004 Jul 27; 110(4):392-8. PubMed ID: 15249498
    [Abstract] [Full Text] [Related]

  • 4. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
    Omran H, Hammerstingl C, Paar WD, Bonn Registry of Alternative Anticoagulation to Prevent Vascular Events.
    Med Klin (Munich); 2007 Oct 15; 102(10):809-15. PubMed ID: 17928964
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.
    Crit Care Med; 2003 May 15; 31(5):1405-9. PubMed ID: 12771610
    [Abstract] [Full Text] [Related]

  • 6. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
    Hammerstingl C, Omran H, Bonn Registry of Alternative Anticoagulation to Prevent Vascular Events.
    Thromb Haemost; 2009 Jun 15; 101(6):1085-90. PubMed ID: 19492151
    [Abstract] [Full Text] [Related]

  • 7. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery.
    Douketis JD, Woods K, Foster GA, Crowther MA.
    Thromb Haemost; 2005 Sep 15; 94(3):528-31. PubMed ID: 16268467
    [Abstract] [Full Text] [Related]

  • 8. Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
    Klamroth R, Gottstein S, Essers E, Landgraf H.
    Vasa; 2010 Aug 15; 39(3):243-8. PubMed ID: 20737383
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    Bui HT, Krisnaswami A, Le CU, Chan J, Shenoy BN.
    Am J Cardiol; 2009 Nov 15; 104(10):1429-33. PubMed ID: 19892063
    [Abstract] [Full Text] [Related]

  • 11. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
    Ramos-Esquivel A, Salazar-Sánchez L.
    Thromb Res; 2013 Oct 15; 132(4):433-6. PubMed ID: 24050826
    [Abstract] [Full Text] [Related]

  • 12. Perioperative bridging of chronic oral anticoagulation in patients undergoing pacemaker implantation--a study in 200 patients.
    Hammerstingl C, Omran H.
    Europace; 2011 Sep 15; 13(9):1304-10. PubMed ID: 21508005
    [Abstract] [Full Text] [Related]

  • 13. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD, Albert M, Champagne MC, Zikos T, Boulanger I, Blais L, Williamson DR.
    J Crit Care; 2011 Aug 15; 26(4):347-51. PubMed ID: 21454037
    [Abstract] [Full Text] [Related]

  • 14. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.
    Thromb Haemost; 2012 May 15; 107(5):916-24. PubMed ID: 22398784
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA, Gurian M, Hegyi T, Drachtman RA.
    Pediatrics; 2004 Sep 15; 114(3):703-7. PubMed ID: 15342842
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP.
    Thromb Res; 2009 Apr 15; 123(6):845-7. PubMed ID: 19038418
    [Abstract] [Full Text] [Related]

  • 20. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul 15; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.